Bausch + Lomb Announces New Scientific Data, Educational Events at the American Academy of Ophthalmology Annual Meeting

  • Seven data presentations and posters include studies evaluating enVista Aspire™ and IC-8® Apthera™ intraocular lenses, XIIDRA® (lifitegrast ophthalmic solution) 5%, MIEBO® (perfluorohexyloctane ophthalmic solution) and the ELIOS™ System*
  • Multiple events will enable surgeons to engage with the latest Bausch + Lomb technology

VAUGHAN, Ontario, Oct. 6, 2026 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and hosting of educational events at the American Academy of Ophthalmology (AAO) annual meeting in New Orleans, La., Oct. 9 – 12.

Scientific posters and presentations will highlight the results of studies evaluating Bausch + Lomb products including the enVista Aspire and IC-8 Apthera premium intraocular lenses (IOLs), XIIDRA, MEIBO and the ELIOS procedure for the treatment of glaucoma. Sponsored educational events will focus on these and other Bausch + Lomb offerings. At the Bausch + Lomb exhibit (booth #519), the company will feature innovations across its portfolio.

Following is a complete list of Bausch + Lomb events and scientific presentations:

Thursday, October 8, 2026 
Integrating Bausch + Lomb's IOLs into Your Advanced Lenses Business

  • 7:15pm CT, Calcasieu, 930 Tchoupitoulas Street
  • Speakers: Alison Early, MD and Jonathan Lam, MD
  • Click here to register for this event

Friday, October 9, 2026 
The Frontline of Modern Cataract Surgery: Ocular Surface Health and Advanced IOL Selection

  • 7:00pm CT, The National WWII Museum, 1043 Magazine Street
  • Speakers: Brandon Ayres, MD and Jai Parekh, MD
  • Consistent evaluation and management of the ocular surface are important considerations when planning cataract surgery with advanced technology IOLs. This case-based program will explore clinical approaches to patient assessment, preoperative planning and patient selection, with strategies intended to help maximize visual potential and patient satisfaction. The discussion will also highlight how Bausch + Lomb's portfolio of ocular surface and surgical products may be incorporated into practice to help support decision-making across the cataract surgery continuum.
  • Click here to register for this event

Saturday, October 10, 2026 
Integrating Bausch + Lomb's IOLs into Your Advanced Lenses Business

  • 7:15pm CT, Arnaud's, 813 Rue Bienville
  • Speakers: Michael Patterson, DO and Zaina Al-Mohtaseb, MD
  • Click here to register for this event

Poster Presentations

  • "Reduced medication burden with maintained visual and structural stability after MIGS procedure in cataract surgery." Sarkisian S.
  • "Outcomes of small-aperture intraocular lens in patients with prior corneal refractive surgery or corneal comorbidities." Stonecipher K.

Posters

  • "Understanding Robust Responders to Lifitegrast in Dry Eye Disease: A Qualitative Study of Eye Care Providers." Donnenfeld E.
  • "24-month outcomes of excimer laser trabeculostomy in patients with open angle glaucoma undergoing cataract surgery." Gallardo M.
  • "Concomitant use of Perfluorohexyloctane Ophthalmic Solution With Contact Lens Wear: A Prospective Open-Label Study." Mah F.
  • "Characteristics of Patients With Improved Tear Film Break-Up Time on Lifitegrast Treatment in a Real-World Setting." Nijm L.
  • "Visual and refractive outcomes following implantation of an enhanced monofocal intraocular lens: A Real-World Study." Sadri E.

Additionally, Bausch + Lomb is sponsoring a number of events at the meeting, including Eyecelerator @ AAO and its Winning Pitch Challenge, AAO's Illuminate the Night event, COBRA After Dark Surgical Retina Rounds, the OWL Signature Event & Awards Ceremony, the Women in Ophthalmology 2026 Awards & Reception, Real World Ophthalmology "After Dark" and the Innovators Pop-Up "Moments of Wonder" event. Bausch + Lomb is also partnering with YoungMD Connect (YMDC) as a supporter of their 2026 Capstone Event, and hosting groups of YMDC members at the booth for leadership meetings and tours throughout the meeting.

*The ELIOS System is not currently cleared by the FDA for use in the United States and no orders are being taken.

###

Indications and Important Safety Information for enVista Aspire & enVista Aspire toric hydrophobic acrylic IOLs

INDICATIONS:

The enVista Aspire™ hydrophobic acrylic IOL (non-preloaded model: EA / preloaded into shuttle models: EPA, EC20A, EC24A) is indicated for primary implantation in the capsular bag of the eye in adult patients for the visual correction of aphakia following removal of a cataractous lens.

The enVista Aspire™ toric hydrophobic acrylic IOL (non-preloaded model: ETA / preloaded into shuttle models: ETPA, ETC20A, ETC24A) is indicated for primary implantation in the capsular bag of the eye in adult patients for the visual correction of aphakia and corneal astigmatism following the removal of a cataractous lens for improved uncorrected distance vision.

DEVICE DESCRIPTIONS:

The enVista Aspire and enVista Aspire toric IOLs use an optical modification of the posterior aspheric surface to create a small continuous increase in IOL power within the central 1.5 mm diameter to slightly broaden the depth of focus.

WARNINGS:

enVista Aspire and enVista Aspire toric IOLs: Physicians considering IOL implantation under any of the following circumstances should weigh the potential risk/benefit ratio: (1) Recurrent severe anterior or posterior segment inflammation or uveitis; (2) Patients in whom the IOL may affect the ability to observe, diagnose, or treat posterior segment diseases; (3) Surgical difficulties at the time of cataract extraction, which might increase the potential for complications (e.g., persistent bleeding, significant iris damage, uncontrolled positive pressure, or significant vitreous prolapse or loss); (4) A distorted eye due to previous trauma or developmental defect in which appropriate support of the IOL is not possible; (5) Circumstances that would result in damage to the endothelium during implantation; (6) Suspected microbial infection; (7) Patients in whom neither the posterior capsule nor zonules are intact enough to provide support.

enVista Aspire toric IOL only: Rotation of the IOL away from the intended axis can reduce its astigmatic correction. Misalignment greater than 30° may increase postoperative refractive cylinder. If necessary, IOL positioning should occur prior to capsule fibrosis and IOL encapsulation.

PRECAUTIONS:

  1. Neither the safety and effectiveness, nor the effects of the Aspire IOL optical design on depth of focus, contrast sensitivity, and subjective visual disturbances (glare, halo, etc.) have been evaluated clinically. MTF testing of the Aspire IOL optical design (used in model ETA) may aid the surgeon in understanding the theoretical image quality expected with the Aspire IOL compared to the enVista monofocal IOL MX60E. However, these do not fully assess all aspects of clinical difficulties under all conditions. Surgeons must weigh the potential benefits of the modified optical design of the Aspire IOL (model ETA) against the potential for risks associated with a degradation in vision quality and the lack of clinical data to characterize the impact of the Aspire IOL optical design on contrast sensitivity and subjective visual disturbance. These considerations may be especially relevant to patients with certain pre-existing ocular conditions (prior corneal refractive surgery, irregular corneal astigmatism, severe corneal dystrophy, macular disease, optic nerve atrophy, etc.) or intraoperative conditions (posterior capsular rupture, complications in which the IOL stability could be compromised, inability to place IOL in capsular bag, etc).
  2. The safety and effectiveness of the IOL have not been substantiated in patients with pre-existing ocular conditions and intraoperative complications. Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the benefit/risk ratio before implanting an IOL in a patient with one or more of these conditions. Physicians considering IOL implantation in such patients should explore the use of alternative methods of aphakic correction and consider IOL implantation only if alternatives are deemed unsatisfactory in meeting the needs of the patient.
  3. Patients with preoperative problems, such as corneal endothelial disease, abnormal cornea, macular degeneration, retinal degeneration, glaucoma, and chronic drug miosis may not achieve the visual acuity of patients without such problems. The physician must determine the benefits to be derived from IOL implantation when such conditions exist.

Adverse Events: As with any surgical procedure, there is risk involved. Potential complications accompanying cataract or implant surgery may include, but are not limited to the following: corneal endothelial damage, infection (endophthalmitis), retinal detachment, vitritis, cystoid macular edema, corneal edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon transient or persistent glaucoma, and secondary surgical intervention. Secondary surgical interventions include but are not limited to: lens repositioning, lens replacement, vitreous aspiration or iridectomy for pupillary block, wound leak repair, and retinal detachment repair.

CAUTION: Federal law restricts these devices to sale by or on the order of a physician.

ATTENTION: This is not all you need to know. Please refer to the enVista Aspire and enVista Aspire toric IOL Directions For Use labeling for a complete listing of indications, full risk and safety information, clinical study information, etc.

IC-8® Apthera™ IOL

INDICATIONS

The IC-8® Apthera™ IOL is indicated for unilateral implantation for the visual correction of aphakia and to create monovision in patients of age 22 or older who have been diagnosed with bilateral operable cataract, who have up to 1.5 D of astigmatism in the implanted eye, and who do not have a history of retinal disease and who are not predisposed to experiencing retinal disease in the future. The device is intended for primary implantation in the capsular bag, in the non-dominant eye, after the fellow eye has already undergone successful implantation (uncorrected distance visual acuity 20/32 or better and best-corrected distance visual acuity 20/25 or better) of a monofocal or monofocal toric IOL that is targeted for emmetropia. The refractive target for the IC-8 Apthera IOL should be -0.75 D. The lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal or monofocaltoric IOL, the lens provides improved intermediate and near visual acuity, while maintaining comparable distance visual acuity.

CONTRAINDICATIONS

(1) Patients with dilated pupil size less than 7.0 mm. (2) Patients with a history of retinal disease including but not limited to, high myopia, diabetes, macular disease, sickle cell disease, retinal tear, retinal detachment, retinal vein occlusion, ocular tumor, uveitis, and patients who are predisposed to experiencing retinal disease in the future.

WARNINGS:

The lens should not be implanted if appropriate intraocular support of the lens is not possible. Severe subjective visual disturbances (e.g., glare, halo, starburst, hazy vision) may occur after device implantation. There is a possibility that these visual disturbances may be significant enough that a patient may request removal of the lens. Contrast sensitivity in eyes implanted with this lens is significantly reduced when compared to the fellow eye implanted with a monofocal or monofocal toric IOL. Although there was no significant reduction in binocular contrast sensitivity in the IDE clinical study, it is essential that prospective patients be fully informed of this visual effect in the implanted eye before giving their consent for unilateral implantation of the lens. Patients should be informed that they may need to exercise caution when engaging in activities that require good vision in dimly lit environments (such as driving at night or in poor visibility conditions). There is a possibility that visual symptoms due to reduced contrast sensitivity may be significant enough that a patient may request removal of the lens. This lens should not be implanted bilaterally because bilateral implantation is expected to cause significant reduction in contrast sensitivity under all lighting conditions. The use of this lens in patients with corneal astigmatism greater than 1.5 D is not recommended. Diagnostic tests in patients implanted with the lens may take longer and require some additional effort from the patient and the physician to perform. Use of some medical lasers to treat certain eye conditions may present potential risks of damaging the FilterRing component of the lens. Removal of the lens may be necessary prior to retinal or vitreal procedures. Surgeons should perform a careful benefit-risk assessment based on individual patient characteristics, weighing all the risks disclosed in the Directions for Use labeling against the benefit of extended depth of focus. Nd:YAG laser capsulotomy treatments may be more difficult to perform and may be less effective in an IC-8® Apthera™ IOL implanted eye. Specific training from Bausch & Lomb, Inc. or its authorized representative related to YAG capsulotomy is required before a surgeon is authorized to implant the IC-8® Apthera™ IOL.

PRECAUTIONS:

Prior to surgery, prospective patients should be informed of the possible risks and benefits associated with this lens and a Patient Information Brochure should be provided to the patient. Patients with a predicted postoperative astigmatism between 1.0 D and 1.5 D may not obtain as great an amount of improvement in intermediate vision compared to patients with lower amounts of astigmatism.

CAUTION: Federal law restricts this device to sale by or on the order of a licensed physician.

ATTENTION: Reference the Directions for Use labeling for a complete listing of important safety information.

MIEBO Indications and Important Safety Information

INDICATION
MIEBO® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

MIEBO is contraindicated in patients with known hypersensitivity to perfluorohexyloctane

MIEBO should not be administered while wearing contact lenses. Contact lenses should be removed before use and for at least 30 minutes after administration of MIEBO

Instruct patients to instill one drop of MIEBO into each eye four times daily

The safety and efficacy in pediatric patients below the age of 18 have not been established

In pivotal trials, the most common ocular adverse reaction was blurred vision (1% to 3% of patients reported blurred vision and conjunctival redness)

Click here for full Prescribing Information for MIEBO.

XIIDRA Indications and Important Safety Information

INDICATION
Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.

In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.

To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.

Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.

Safety and efficacy in pediatric patients below the age of 17 years have not been established.

Click here for full Prescribing Information for Xiidra.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we've evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we're turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.


Media Contact:
Caryn Marshall
[email protected]
(908) 493-1381

© 2026 Bausch + Lomb.
APT.0016.USA.26

ORIGINAL
Back to Press Releases